1-3 of 3
Raphael Costa Bandeira de Melo
Close
Sort by
Journal Articles

Outcomes of Conservative Indication Criteria for First-Line Treatment in Chronic Lymphocytic Leukemia: Insights from the Brazilian Registry of CLL

Fernanda de Morais Marques, Verena Pfister, Flavia Parra, Leila Perobelli, Mihoko Yamamoto, Valeria Buccheri, Raphael Costa Bandeira de Melo, Sérgio Costa Fortier, Rodrigo Santucci, Marcelo Bellesso, Glaciano Ribeiro, Nelson Hamerschlak, Abel Costa Neto, Vera Figueiredo, Laura Maria Fogliatto, Sergio Augusto B Brasil, Marcelo Lacerda, Matheus Vescovi Goncalves, Carlos Chiattone, Celso Arrais-Rodrigues
Journal: Blood
Blood (2023) 142 (Supplement 1): 6534.
https://doi.org/10.1182/blood-2023-190590
Published: 2023
Journal Articles

Ezrin Is a Potential Druggable Target in Chronic Lymphocytic Leukemia

Jean Carlos Lipreri Da Silva, Felipe Saldanha-Araujo, Raphael Costa Bandeira de Melo, Hugo Passos Vicari, Amandda Évelin Silva De Carvalho, Eduardo M Rego, Valeria Buccheri, João Agostinho Machado-Neto
Journal: Blood
Blood (2022) 140 (Supplement 1): 12359–12360.
https://doi.org/10.1182/blood-2022-160267
Published: 2022
Journal Articles

Screening for Acquired Von Willebrand Syndrome in Myelofibrosis - Poor Correlation with Bleeding Risk

Raphael Costa Bandeira de Melo, Tania Rubia Rocha, Alexandre Eiji Kayano, Guilherme Souza Villar Cassimiro Fonseca, Vanderson Rocha, Wellington F Silva, Fernanda S Seguro
Journal: Blood
Blood (2022) 140 (Supplement 1): 9713.
https://doi.org/10.1182/blood-2022-166408
Published: 2022